~~<i id='3A836EEC86'><strike id='3A836EEC86'><tt id='3A836EEC86'><pre id='3A836EEC86'></pre></tt></strike></i>~~

Home» Wikipedia» entertainment

entertainment

author：knowledge 2025-08-06 14:08:23 Page View：5194

CMS Administrator Chiquita Brooks-LaSure Chip Somodevilla/Getty Images

WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced this week — news that adds even more pressure on Medicare’s unprecedented restrictions on coverage.

Medicare has so far held firm on its plans to require patient registries for the entire class of anti-amyloid Alzheimer’s drugs, even after they are fully approved.

Pharmaceutical groups and patient advocates are increasingly fighting that approach.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Making the case for fair compensation in clinical trials
Next article： Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

explore

Anesthesiologist group: stop taking Ozempic before surgery

EspeciallyinthefirstweeksoftakingdrugslikeOzempic,foodstayslongerinthestomach—aprobleminsurgeries.Ad

Addressing health care workers' trauma can help fight burnout

RicardoArduengo/APBurnoutisagrowingcrisisinhealthcare:Morethan50%ofhealthcareprofessionalsreportsymp

The high cost of giving birth even with insurance

AdobeTheburdenofhighhealthcarecostsandmedicaldebtintheU.S.isnosecret.Medicaldebtaffectsoneinfiveadul

What a koala virus tells us about the human genome

ADOBEThehumangenomeisnotentirelyhuman.Some8%ofourDNA,infact,originatedinviruses,remnantsofancientsin